Orthofix Medical Inc. filings document regulatory disclosures for a medical technology company focused on spinal implants, therapeutic solutions, limb reconstruction systems, biologics and enabling technologies. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary net sales, guidance-related exhibits and non-GAAP measures including constant currency, free cash flow, adjusted gross profit and adjusted margin.
The company’s proxy and governance filings cover director elections, executive compensation, equity award disclosures, auditor ratification and common-share voting matters. Other current reports document Spine leadership changes, annual meeting results and board committee appointments.
Orthofix Medical Inc. (OFIX) President, Global Limb Recon Patrick Fisher sold 150 shares of common stock on October 1, 2026, at $9.44 per share. The sale was made under a Rule 10b5-1 trading plan adopted May 29, 2026. His reported direct holdings after the transaction were 50,919 shares, including 36,028 previously reported restricted stock units.
Orthofix Medical Inc. (OFIX) reported purchases of its common stock by Juniper Targeted Opportunity Fund, L.P.: 120,000 shares on September 18, 2026, at a weighted average of $8.7393 per share, and 190,000 shares on September 21, 2026, at a weighted average of $8.8599 per share. The reported price ranges were $8.65–$8.81 and $8.63–$8.98, respectively. Juniper Investment Company, LLC, John A. Bartholdson, and Alexis P. Michas were identified as 10% owners. Juniper Investment Company was identified as the fund’s investment manager, and Bartholdson and Michas as managing members who shared voting and dispositive power. All three disclaimed beneficial ownership except to the extent of their pecuniary interests. No Rule 10b5-1 plan is reported.
Orthofix Medical Inc. (symbol: OFIX) is the issuer of record for a Form 4 filing submitted to the SEC.
Orthofix Medical Inc. (OFIX) reported that Patrick Fisher, its President, Global Limb Recon, sold 150 shares of common stock on September 1, 2026 at $9.39 per share in an open-market transaction under a Rule 10b5-1 trading plan. After this sale, he directly holds 51,069 shares, which include 36,028 previously reported restricted stock units.
Orthofix Medical Inc. (OFIX) is the issuer in a Form 144 filing by Patrick Fisher, an officer, covering a proposed resale of company common stock under Rule 144. The notice contemplates the sale of 450 shares of Orthofix common stock through Morgan Stanley Smith Barney on NASDAQ.
The 450 shares relate to Restricted Stock Units acquired from the issuer on 08/15/2025. The filing also reports that during the past three months Patrick Fisher sold 1,295 shares of Orthofix common stock on 08/18/2026.
Orthofix Medical Inc. (OFIX) reported that Patrick Fisher, President, Global Limb Recon, sold 1,295 shares of common stock on 2026-08-18 at $10.09 per share. The sale was executed solely to satisfy tax withholding obligations under a pre-approved, mandatory sell-to-cover arrangement and involved no discretion by Fisher. Following this transaction, he holds 51,219 shares directly, including 36,028 restricted stock units and 1,881 shares acquired under Orthofix's Stock Purchase Plan.
Orthofix Medical Inc. (symbol: OFIX) is the issuer of record for a Form 4 filing submitted to the SEC.
Armistice Capital, LLC and Steven Boyd report updated beneficial ownership of Orthofix Medical Inc. common stock in Amendment No. 8 to their Schedule 13G. As of June 30, 2026, they report beneficial ownership of 3,264,000 shares, representing 8.01% of Orthofix’s common stock. They hold shared voting and dispositive power over all 3,264,000 shares and no sole voting or dispositive power. The shares are directly held by Armistice Capital Master Fund Ltd., for which Armistice Capital serves as investment manager under an Investment Management Agreement. The Master Fund has the right to receive dividends and sale proceeds from the reported securities.
Orthofix Medical reported Q2 2026 net sales of $210.9 million, up 3.8% on a reported basis and 4.7% on a pro forma constant-currency basis versus Q2 2025. Growth was driven by double‑digit constant‑currency increases in Global Spine Fixation and Global Limb Reconstruction, 3% growth in Therapeutic Solutions, and stabilizing Biologics.
GAAP gross margin was 71.0%, or 71.7% on an adjusted basis. The company recorded a net loss of $15.8 million, or $0.39 per share, slightly wider than a year ago, while non‑GAAP adjusted EBITDA was $20.1 million, or 9.6% of pro forma net sales, modestly below the prior-year quarter. Cash, cash equivalents and restricted cash were $104.4 million at June 30, 2026, with long‑term debt of $221.6 million; cash declined sequentially mainly due to arbitration award and settlement payments to former executives.
Reflecting Q2 performance and restored Medicare reimbursement for non‑invasive bone growth stimulators, Orthofix raised its 2026 non‑GAAP pro forma guidance to net sales of $845–$855 million and adjusted EBITDA of $95–$98 million, which at the midpoint implies about 5% constant‑currency revenue growth and 80 basis points of adjusted EBITDA margin expansion versus 2025.